1. A measuring arrangement for measuring clearance between a bearing internal part and a fixed bearing external part of a bearing, in particular in an aircraft or spacecraft, the measuring arrangement comprising an adjusting device for adjusting the bearing internal part relative to the fixed bearing external part and a measuring device for measuring the adjustment carried out, wherein the adjusting device comprises a measuring element which is securable in the bearing internal part, wherein the measuring element is configured as a measuring bolt which is insertable into a bore of the bearing internal part, wherein the adjusting device comprises an engagement means which can brought into engagement with the measuring element, wherein the adjusting device comprises a rotational axis about which the engagement means is pivotable to carry out the adjusting of the bearing internal part relative to the fixed bearing external part, wherein the adjusting of the bearing internal member is carried out radially with respect to the fixed bearing external part, wherein the engagement means comprises at least one jaw part for partially engaging around the measuring bolt on its circumference, wherein the at least one jaw part is configured to be flat, such that it is insertable between a bearing fitting and a bearing fork of the bearing towards the measuring bolt.
2. The measuring arrangement according to claim 1, wherein the adjusting device acts directly on the bearing internal part.
3. The measuring arrangement according to claim 1, wherein the adjusting device comprises fastening means on its rotational axis, by means of which the adjusting device is securable to a bearing fitting of the bearing.
4. The measuring arrangement according to claim 3, wherein the fastening means are configured as a clamping device for clamping the adjusting device to the bearing fitting.
5. The measuring arrangement according to claim 1, wherein a force measuring device is provided for a repeatable measurement of the adjustment, by which a force applied by the adjusting device to the bearing internal part is measurable.
6. The measuring arrangement according to claim 5, wherein the force measuring device is configured as a resilient lever by which the engagement means is pivotable about the rotational axis.
7. The measuring arrangement according to claim 5 or 6, wherein a force which is divertable from a resilient deformation of the resilient lever is readable on a scale of the force measuring device.
8. The measuring arrangement according to claim 1, wherein the engagement means comprises two jaw parts for engaging around the measuring bolt at opposing ends.
9. The measuring arrangement according to claim 1, wherein the adjusting device comprises positioning means within its rotational axis for positioning the adjusting device relative to the bearing external part.
10. The measuring arrangement according to claim 1, wherein the measuring device is configured as a dial gauge.
11. The measuring arrangement according to claim 10, wherein the dial gauge comprises a measuring sensor which can be positioned under spring tension on the measuring element or the bearing internal part.
12. The measuring arrangement according to claim 11, wherein the measuring sensor is insertable into a recess in the measuring bolt and can be positioned on an internal wall of the bearing internal part.
13. A method for measuring clearance between a bearing internal part and a fixed bearing external part, which are fitted in an aircraft or spacecraft, comprising the following method steps:
adjusting the bearing internal part from a first bearing position of the bearing internal part on the bearing external part to a second bearing position on the bearing external part opposing the first bearing position by means of an adjusting device for adjusting the bearing internal part relative to the bearing external part;
measuring the adjustment with a measuring device;
wherein a bearing bolt of the bearing is replaced before the adjustment of the bearing internal part relative to the bearing external part by a measuring element;
wherein after the replacement of the bearing bolt by the measuring element, said measuring element is brought into engagement with an engagement means of the adjusting devices; and
wherein the engagement means for adjusting the bearing internal part is pivoted from the first bearing position into the second bearing position, wherein the bearing internal part is adjusted radially with respect to the fixed bearing external part.
14. The method according to claim 13, wherein at the first and second bearing position respectively the same amount of force is applied to the bearing internal part for pressing the bearing internal part against the bearing external part with the adjusting device.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-15. (canceled)
16. A cineole-containing dosage form for peroral application in the form of a capsule, where the dosage form is designed as a capsules-in-capsule system,
where the capsules-in-capsule system has an outer capsule (outside capsule) having an outer capsule shell and a plurality of inner capsules (inside capsules) located in the outer capsule, where the inner capsules are completely enclosed by the capsule shell of the outer capsule and the inner capsules are designed as microcapsules which each contain the active ingredient 1,8-cineole and
where the inner capsules comprise 1,8-cineole together with at least one physiologically acceptable carrier which is miscible with 1,8-cineole or soluble therein, and is liquid at 20\xb0 C. and atmospheric pressure, where the carrier is selected from the group of triglycerides.
17. The dosage form as claimed in claim 16, wherein the inside capsules are present in the form of matrix capsules or in the form of coreshell capsules.
18. The dosage form as claimed in claim 16, wherein the capsule shell material or the capsule matrix material of the inside capsules comprises at least one pharmacologically acceptable polymer or consists thereof, which polymer is selected from synthetic, natural or nature-identical polymers and polymerizates from the group consisting of (A) polysaccharides, alginates, cellulose and cellulose derivatives, chitosans, starch and starch derivatives, agar agar, carrageenans, pectins, galactomannans, guarans, dextrans, xanthans, glucans and gum Arabic; (B) proteins, gelatin and caseinates; (C) polylactides, homo- and copolymers of lactic acid; (D) amino resins; (E) poly(meth)acrylates; (F) polyureas; (G) polyelectrolytes or polyelectrolyte complexes; (H) waxes; (I) paraffins; (J) colloids and hydrocolloids, colloids and hydrocolloids based on polysaccharide or protein; and mixtures and combinations thereof, particularly preferably from the group of (A) polysaccharides, in particular alginates, cellulose and cellulose derivatives, chitosans, starch and starch derivatives, agar agar, carrageenans, pectins, galactomannans, guarans, dextrans, xanthans, glucans and gum Arabic; (B) proteins, in particular gelatin and caseinates; (C) polylactides, in particular homo- and copolymers of lactic acid; and mixtures and combinations thereof.
19. The dosage form as claimed in claim 16, wherein the inside capsules are obtainable by means of dropletization processes, interfacial polycondensation processes, interfacial polyaddition processes, solvent evaporation processes, spray-drying processes or phase separation processes.
20. The dosage form as claimed in claim 16, wherein the ratio of the diameter of the inside capsules to the diameter of the outside capsule is at least 1:5 and up to 1:100,000.
21. The dosage form as claimed in claim 16, wherein the dosage form comprises 1,8-cineole as the sole active ingredient.
22. The dosage form as claimed in claim 16, wherein the dosage form comprises 1,8-cineole at least with at least one further active ingredient selected from terpenes.
23. The dosage form as claimed in claim 16, wherein the carrier is selected from the group of medium chain triglycerides (MCT) and triglycerides with C6-C12-fatty acid radicals.
24. The dosage form as claimed in claim 16, wherein the carrier is used in a 1,8-cineolecarrier quantitative ratio in the range from 100:1 to 1:100.
25. The dosage form as claimed in claim 16, wherein the dosage form comprises the active ingredient 1,8-cineole in absolute amounts of from 10 to 1,000 mg
26. The dosage form as claimed in claim 16, wherein the dosage form comprises the active ingredient 1,8-cineole in relative amounts of from 0.01 to 99% by weight.
27. The dosage form as claimed in claim 16, wherein the dosage form is designed to be resistant to gastric juice, but soluble in the small intestine.
28. The dosage form as claimed in claim 16, wherein at least on of the outside capsule and the inside capsules is provided with a gastric juice-resistant, small intestine-soluble coating or shell.
29. A process for producing a cineole-containing dosage form as claimed in claim 16,
where firstly microcapsules which each contain the active ingredient 1,8-cineole together with at least one physiologically acceptable carrier that is miscible with 1,8-cineole or soluble therein, and is liquid at 20\xb0 C. and atmospheric pressure are produced, where the carrier is selected from the group of triglycerides, and
where a plurality of the microcapsules produced in this way is completely enclosed by an outer capsule shell and is combined or integrated to give a capsules-in-capsule system with the microcapsules as inner capsules.
30. The process as claimed in claim 29, wherein the production of the microcapsules is carried out by means of dropletization processes, interfacial polycondensation processes, interfacial polyaddition processes, solvent evaporation processes, spray-drying processes or phase separation processes.
31. The process as claimed in claim 29, wherein the microcapsules are produced by means of a dropletization process, where a microcapsule-forming starting material is dropletized in the presence of 1,8-cineole and the carrier (excipient) and solidified to give microcapsules containing 1,8-cineole.
32. A method for the prophylactic or therapeutic treatment of a human or animal body suffering from inflammatory, infection-exacerbated or allergic diseases, the method comprising administering the dosage form as claimed in claim 16 in an efficient amount.
33. The method as claimed in claim 32, wherein the disease to be treated is selected from the group consisting of autoimmune diseases; colds and flu infections and diseases and infections associated therewith, infections of the upper and lower respiratory tracts, rhinitis, sinusitis; respiratory tract diseases, bronchopulmonary diseases, bronchitis, bronchial asthma and chronic obstructive pulmonary diseases (COPD); inflammatory diseases of the bile ducts, cholecystisis and cholangitis; inflammatory diseases of the lower urinary tract, glomerulonephritis, pyelonephritis, cystitis and uritritis; inflammatory diseases of the intestine, Crohn’s disease and colitis ulcerosa; inflammatory or allergic skin diseases, eczemas and dermatitis; rheumatoid diseases, rheumatic diseases, rheumatism and diseases of the rheumatic category; systemically corticosteroid-dependent diseases and diseases which are treated with systemically administered corticosteroids.
34. The method as claimed in claim 32, wherein the 1,8-cineole is administered in daily doses of from 50 to 3,000 mgdiem.
35. A drug or medicinal product, comprising the cineole-containing dosage form as claimed in claim 16.
36. The drug or medicinal product as claimed in claim 35, wherein the drug or medicinal product is provided for an administration of 1,8-cineole in a daily dose of from 50 to 3,000 mgdiem.